comparemela.com

Latest Breaking News On - Oryzon genomics - Page 3 : comparemela.com

ORYZON announces positive results from planned interim analysis of PORTICO, a Phase 2b adaptive trial in Borderline Personality Disorder

Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the trial

Carlos buesaMichael ropackiDouglasv fallerData monitoring committeeOryzon genomicsIndependent data monitoring committeeChief medical officerGlobal chief medical officerKabuki syndromeChief executive officer

Oryzon Genomics - New clinical candidate expands CNS portfolio

Oryzon Genomics has nominated a new central nervous system (CNS) clinical development candidate, ORY-4001, for the treatment of rare CNS disorders including Charcot-Marie-Tooth (CMT) disease and amyotrophic

Dennis riedlResearch foundationOryzon genomicsOryzonGenomicsLinicalCandidateXpandsPortfolio

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

CopenhagenKøavnDenmarkNew yorkUnited statesMadridSpainBostonMassachusettsColumbia universityBarcelonaComunidad autonoma de catalunaSpanishDanishCarlos buesaDevelopment agreement

ORYZON Announces First Patient In in NET, a Collaborative

Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECsPart of a.

BostonMassachusettsUnited statesSpainBarcelonaComunidad autonoma de catalunaMadridPatricia coboAshleyr robinsonSaikat nandiDouglas fallerNamrata vijayvergiaDevelopment agreementUs national cancer instituteNuclear dynamicsLifesci advisors

ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas

ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas

United statesSpainBarcelonaComunidad autonoma de catalunaDouglas fallerNamrata vijayvergiaDevelopment agreementUs national cancer instituteNuclear dynamicsCancer epigenetics instituteFox chase cancer centerOryzon genomicsAssistant chiefGastrointestinal medical oncologyGlobal chief medical officerSmall cell lung cancer

vimarsana © 2020. All Rights Reserved.